CD38 and acute lymphoblastic leukemia: Furthermore, preclinical studies have shown that isatuximab has significant activity against ALL cell lines with a robust ADCC and ADCP effect, with a clear association between the expression of CD38 and isatuximab activity in both T‐ALL and B‐ALL14